P409: Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: Results from a real-world observational studyECCO '18 Vienna
2018
P411: Benefits of implementing a rapid access clinic in a high-volume inflammatory bowel disease centre: Accessibility, resource utilisation and outcomesECCO '18 Vienna
2018
P413: Relative frequency of relapses in patients with ulcerative colitis and Crohn's disease treated with mesenchymal stromal cells: Five-years of follow-upECCO '18 Vienna
2018
P414: Loss of response to anti-TNF in inflammatory bowel disease in a Portuguese centreECCO '18 Vienna
2018
P416: Metabolite measurement for thiopurine therapy in inflammatory bowel diseaseECCO '18 Vienna
2018
P419: Frequency of inadequate response to anti-tumour necrosis factor therapy in patients with ulcerative colitis. Preliminary results from POLIBD studyECCO '18 Vienna
2018
P420: Effectiveness and safety of biosimilar infliximab (remsima) in a real-life setting in 84 patients with Crohn’s disease and ulcerative colitisECCO '18 Vienna
2018
P422: Sustained corticosteroid-free remission with vedolizumab in moderate-to-severe ulcerative colitis: A post hoc analysis of GEMINI 1ECCO '18 Vienna
2018
P423: Epidemiology, diagnostic work-up and pharmacological requirements of inflammatory bowel disease (IBD) in Spain: Results from the nationwide EpidemIBD study of GETECCUECCO '18 Vienna
2018
P424: Monitoring response to adalimumab therapy in Crohn’s disease patients by bowel ultrasound: Sub-analysis from TRUSTECCO '18 Vienna
2018